Table 2

Changes in BCVA, CMT ,SRFH and SFCT during the follow-up period in the treatment and control groups

Baseline1 Month2 Months
LogMAR BCVATreatment group0.25±0.180.14±0.15*0.05±0.09*
Control group0.25±0.220.19±0.200.14±0.18*
p0.7870.6450.124
CMT (μm)Treatment group535.67±116.94354.88±108.64*248.72±45.58†
Control group501.33±149.39401.36±125.33*307.33±95.42*
p0.4390.4220.048*
SRFH (μm)Treatment group340.61±126.84155.75±116.31*43.22±61.02†
Control group315.17±154.17199.27±131.79*114.58±97.40*
p0.6020.5120.017*
SFCT (μm)Treatment group502.50±87.38456.00±81.11†427.44±74.37†
Control group480.33±102.38456.18±98.94463.75±100.63
p0.6020.9420.215
  • Data are presented as mean±SD.

  • *Indicates significant difference from baseline (p<0.05, Wilcoxon signed-rank test).

  • †Indicates significant difference from baseline (p<0.01, Wilcoxon signed-rank test).

  • BCVA, best corrected visual acuity; CMT, central macular thickness; logMAR, logarithm of the minimum angle of resolution; SFCT subfoveal choroidal thickness; SRFH, height of subretinal fluid.